(NASDAQ: XERS) Xeris Biopharma Holdings's forecast annual revenue growth rate of 18.81% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.66%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.42%.
Xeris Biopharma Holdings's revenue in 2026 is $335,414,000.On average, 9 Wall Street analysts forecast XERS's revenue for 2026 to be $72,043,868,916, with the lowest XERS revenue forecast at $68,915,252,465, and the highest XERS revenue forecast at $74,833,369,598. On average, 9 Wall Street analysts forecast XERS's revenue for 2027 to be $89,508,331,028, with the lowest XERS revenue forecast at $81,921,983,095, and the highest XERS revenue forecast at $97,652,579,097.
In 2028, XERS is forecast to generate $101,687,327,468 in revenue, with the lowest revenue forecast at $94,482,028,975 and the highest revenue forecast at $109,310,139,462.